MA33552B1 - Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques - Google Patents

Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques

Info

Publication number
MA33552B1
MA33552B1 MA34459A MA34459A MA33552B1 MA 33552 B1 MA33552 B1 MA 33552B1 MA 34459 A MA34459 A MA 34459A MA 34459 A MA34459 A MA 34459A MA 33552 B1 MA33552 B1 MA 33552B1
Authority
MA
Morocco
Prior art keywords
spiro
enantiomers
therapeutic agents
oxindole compounds
enantiomer
Prior art date
Application number
MA34459A
Other languages
Arabic (ar)
English (en)
Inventor
Mikhail Chafeev
Jianmin Fu
Jean-Jacques Cadieux
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42416878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33552(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA33552B1 publication Critical patent/MA33552B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'énantiomère (S) du composé de formule (I) ou un solvate pharmaceutiquement acceptable ou un promédicament de celui-ci. Cet énantiomère (S) est utile pour le traitement de maladies ou affections, telles que la douleur, qui sont atténuées ou soulagées par la modulation de canaux sodiques sensibles au voltage.
MA34459A 2009-06-29 2011-12-16 Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques MA33552B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22142409P 2009-06-29 2009-06-29
PCT/US2010/040187 WO2011002708A1 (fr) 2009-06-29 2010-06-28 Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques

Publications (1)

Publication Number Publication Date
MA33552B1 true MA33552B1 (fr) 2012-09-01

Family

ID=42416878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34459A MA33552B1 (fr) 2009-06-29 2011-12-16 Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu'agents thérapeutiques

Country Status (34)

Country Link
US (4) US8450358B2 (fr)
EP (3) EP3156407A1 (fr)
JP (3) JP2012532107A (fr)
KR (1) KR101751378B1 (fr)
CN (2) CN104650106A (fr)
AR (1) AR077252A1 (fr)
AU (1) AU2010266549B2 (fr)
BR (1) BRPI1012129A2 (fr)
CA (1) CA2764878C (fr)
CL (1) CL2011003335A1 (fr)
CO (1) CO6470866A2 (fr)
CY (1) CY1117776T1 (fr)
DK (1) DK2448943T3 (fr)
EC (1) ECSP11011512A (fr)
ES (2) ES2600160T3 (fr)
HR (2) HRP20160732T1 (fr)
HU (1) HUE029658T2 (fr)
IL (3) IL217285A (fr)
MA (1) MA33552B1 (fr)
MX (2) MX2012000028A (fr)
MY (1) MY159099A (fr)
NZ (1) NZ596903A (fr)
PE (2) PE20160216A1 (fr)
PH (2) PH12011502619A1 (fr)
PL (2) PL2448943T3 (fr)
PT (1) PT2448943T (fr)
RU (1) RU2535667C2 (fr)
SG (1) SG176307A1 (fr)
SI (1) SI2448943T1 (fr)
SM (1) SMT201600203B (fr)
TN (1) TN2011000664A1 (fr)
TW (1) TWI465452B (fr)
WO (1) WO2011002708A1 (fr)
ZA (1) ZA201108960B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
CL2007002953A1 (es) * 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
JP5460324B2 (ja) 2006-10-12 2014-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド 治療剤としてのスピロ−オキシインドール化合物の使用
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010045197A1 (fr) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
DK2448938T5 (en) 2009-06-29 2015-10-05 Incyte Corp Pyrimidinones AS PI3K inhibitors
US8445696B2 (en) * 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011047173A2 (fr) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques à usage oral
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
CA2788440A1 (fr) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques de compose spiro-oxindole pour administration topique et leur utilisation en tant qu'agents therapeutiques.
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012049555A1 (fr) 2010-10-13 2012-04-19 Lupin Limited Composés spirocycliques en tant que modulateurs de canaux sodiques dépendants du voltage
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
WO2012125629A1 (fr) 2011-03-14 2012-09-20 Incyte Corporation Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
HRP20170285T1 (hr) 2011-09-02 2017-04-21 Incyte Holdings Corporation Heterociklilamini kao inhibitori pi3k
EP2638908A1 (fr) * 2012-03-16 2013-09-18 Phytotox SpA Poison paralysant de mollusque
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
HK1205114A1 (en) * 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
EP2956118A1 (fr) * 2013-02-13 2015-12-23 Novartis AG Agents analgésiques oculaires topiques
JP6463580B2 (ja) 2013-12-13 2019-02-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
US20150216794A1 (en) * 2014-02-05 2015-08-06 IVAX International GmbH Methods of treating pain associated with osteoarthritis of a joint with a topical formulation of a spiro-oxindole compound
EP3126360A1 (fr) 2014-03-29 2017-02-08 Lupin Limited Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016109795A1 (fr) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Funapide et difluorofunapide deutérés
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
MX373232B (es) 2015-02-27 2020-05-08 Incyte Holdings Corp Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación.
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
AU2016370554B2 (en) 2015-12-18 2018-11-29 Merck Sharp & Dohme Corp. Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
WO2017218920A1 (fr) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Synthèse asymétrique de funapide
CN114409665A (zh) * 2016-06-16 2022-04-29 泽农医药公司 螺-吲哚酮化合物的固态形式
WO2018163077A1 (fr) 2017-03-08 2018-09-13 Lupin Limited Composés indanyle utilisés en tant que modulateurs de canaux sodiques dépendant de la tension
WO2018163216A1 (fr) 2017-03-10 2018-09-13 Council Of Scientific & Industrial Research Composés de spirooxindole en tant qu'inhibiteurs de gsk3β et leur procédé de préparation
KR102714561B1 (ko) 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
MX2020003821A (es) 2017-10-10 2023-01-12 Biogen Inc Proceso de elaboración de espiroderivados.
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 疼痛を処置する方法
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
CN112689629B (zh) 2018-07-09 2024-04-23 利伯研究所公司 用于抑制Nav1.8的哒嗪化合物
US12234221B2 (en) 2018-07-09 2025-02-25 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NAV1.8
FI3851436T3 (fi) 2018-09-10 2024-09-03 Kaken Pharma Co Ltd Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke
WO2020146682A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides utilisés en tant que modulateurs de canaux sodiques
WO2020146612A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters et carbamates utilisés en tant que modulateurs de canaux sodiques
US12359551B2 (en) 2019-02-05 2025-07-15 Magnetic Variation Services, Llc Geosteering methods and systems for improved drilling performance
WO2020163372A1 (fr) 2019-02-05 2020-08-13 Motive Drilling Technologies, Inc. Affichage de fond de trou
WO2020176763A1 (fr) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8
WO2020219867A1 (fr) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur
EP4027979A4 (fr) 2019-09-09 2023-10-04 Pacira Therapeutics, Inc. Gels thermodurcissables à libération prolongée comprenant des bloqueurs de canaux sodiques et leurs procédés de fabrication
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
WO2022192427A1 (fr) 2021-03-10 2022-09-15 Pacira Therapeutics, Inc. Gels thermodurcissables à libération prolongée comprenant des bloqueurs de canaux sodiques et leurs méthodes de fabrication
US20240368135A1 (en) 2021-06-04 2024-11-07 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221939A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Analogues de n-(hydroxyalkyl(hetero)aryl)tetrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
KR20240031300A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드
AU2022285758A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
EP4346818B1 (fr) 2021-06-04 2025-12-03 Vertex Pharmaceuticals Incorporated Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide
RU2763140C1 (ru) * 2021-06-29 2021-12-27 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 4-[2-(гидроксиметил)-фениламино]-6',6'-диметил-1'-(2-фторфенил)-3-(4-хлорбензоил)-6',7'-дигидро-5Н-спиро[фуран-2,3'-индол]-2',4',5(1'H,5'H)-трион в качестве средства, обладающего противомикробной активностью
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
CN119522214A (zh) 2022-04-22 2025-02-25 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
US20250388541A1 (en) 2022-04-22 2025-12-25 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
AU2024306684A1 (en) * 2023-06-28 2025-08-07 Avelos Therapeutics Inc. Substituted spiro compound derivatives and their pharmaceutical use
WO2025090511A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de modulateurs de canaux sodiques et formes solides de ceux-ci pour le traitement de la douleur
WO2025090480A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
WO2025090516A1 (fr) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Procédés de préparation de composés pour le traitement de la douleur et de formes solides de ceux-ci
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (fr) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Composés dérivés d'oxazolidone et leur utilisation dans le traitement de la douleur chronique et aiguë
WO2026030525A1 (fr) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Formes galéniques et schémas posologiques de zilvétrigine pour le traitement de la douleur

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3189617A (en) 1961-02-03 1965-06-15 Sterling Drug Inc 1-aryloxindoles and their preparation
DE1956237A1 (de) 1969-11-08 1971-05-13 Basf Ag Spiro-pyrrolizidon-oxindole
DE2113343A1 (de) 1971-03-19 1972-09-21 Thiemann Chem Pharm Fab Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung
US3723459A (en) 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CH577461A5 (fr) 1975-08-13 1976-07-15 Robins Co Inc A H
US4670566A (en) 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4440785A (en) 1980-10-30 1984-04-03 A. H. Robins Company, Inc. Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en) 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja) 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4569942A (en) 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
JPS6130554A (ja) * 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
US4690943A (en) 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4721721A (en) 1984-12-18 1988-01-26 Rorer Pharmaceutical Corporation 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
WO1993012786A1 (fr) 1986-07-10 1993-07-08 Howard Harry R Jr Derives d'indolinone
CA1322197C (fr) * 1987-07-17 1993-09-14 Bernd Buchmann Derives 9-halogene-(z)-prostaglandine, procede pour leur production et leur utilisation comme agents pharmaceutiques
US5182289A (en) 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
ES2110965T3 (es) 1989-07-25 1998-03-01 Taiho Pharmaceutical Co Ltd Derivado de oxoindol.
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5484778C1 (en) 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
EP0558521A1 (fr) 1990-11-22 1993-09-08 Janssen Pharmaceutica N.V. Derives d'acide isonicotinique et composes spiroapparentes a action herbicide
US5116854A (en) 1991-06-28 1992-05-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
CA2140440A1 (fr) 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) et disulfides appparentes (selenides) qui inhibent les proteine-tyrosine-kinases et qui ont des proprietes antitumorales
US5278162A (en) 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
US5776936A (en) 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
US5298522A (en) 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
AT400950B (de) 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
US5763471A (en) 1994-04-07 1998-06-09 Cemaf Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products
FR2722195B1 (fr) 1994-07-07 1996-08-23 Adir Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618819A (en) 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
ES2153907T3 (es) 1994-12-22 2001-03-16 Smithkline Beecham Plc Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CA2235686C (fr) 1995-10-24 2007-06-26 Sanofi Derives 3-spiro-indolin-2-one comme ligands des recepteurs de la vasopressine et/ou de l'ocytocine
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
HUP9600855A3 (en) 1996-04-03 1998-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing tenidap
JPH1095766A (ja) 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1998031378A1 (fr) 1997-01-20 1998-07-23 Immodal Pharmaka Gesellschaft Mbh Procede et substances pour liberer un facteur de croissance issu des cellules endotheliales, facteur de croissance libere selon ce procede, et son utilisation
NO317155B1 (no) * 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
ES2196527T3 (es) * 1997-02-10 2003-12-16 Ono Pharmaceutical Co Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo.
EP0981327B1 (fr) 1997-05-07 2002-11-06 Galen (Chemicals) Limited Dispositifs intravaginaux servant a administrer du testosterone ou des precurseurs de testosterone
ATE260254T1 (de) * 1997-12-25 2004-03-15 Ono Pharmaceutical Co Omega-cycloalkyl-prostaglandin e2 derivate
JP4087938B2 (ja) * 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
JP4334766B2 (ja) 1998-04-01 2009-09-30 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物およびその用途
US20040038970A1 (en) 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US6235780B1 (en) * 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
WO2000006556A1 (fr) 1998-07-27 2000-02-10 Abbott Laboratories Antiproliferants a base d'oxazolines substituees
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
EP1183033B1 (fr) 1999-05-21 2006-03-01 Bristol-Myers Squibb Company Pyrrolotriazines inhibiteurs de kinases
PL352911A1 (en) 1999-07-21 2003-09-22 Astrazeneca Ab New compounds
MXPA02000625A (es) 1999-07-21 2002-07-02 Boehringer Ingelheim Pharma Pequenas moleculas utiles en el tratamiento de enfermedades inflamatorias.
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU1846501A (en) 1999-11-26 2001-06-04 Bionomics Limited Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
WO2002030868A1 (fr) 2000-10-13 2002-04-18 Bristol-Myers Squibb Company Ouvreurs selectifs de canaux potassiques maxi-k, fonctionnant sous des conditions de concentration calcique intracellulaire elevee, procedes et utilisations associes
EP1341759B1 (fr) 2000-11-10 2006-06-14 Eli Lilly And Company Agonistes du recepteur beta-3 d'oxindole 3-substitue
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
JP2005514366A (ja) 2001-11-20 2005-05-19 イーライ・リリー・アンド・カンパニー ３−置換オキシインドールβ３アゴニスト
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
WO2003064425A1 (fr) 2002-01-28 2003-08-07 Pfizer Japan Inc. Composes spiropiperidine n-substitues utilises comme ligands pour le recepteur de orl-1
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2003078394A1 (fr) 2002-03-15 2003-09-25 Eli Lilly And Company Derives de dihydroindol-2-one modulant le recepteur nucleaire de l'hormone steroide
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
EP1531806A4 (fr) 2002-06-25 2005-09-21 Wyeth Corp Utilisation de derives de thio-oxindole dans le traitement d'etats pathologiques lies aux hormones
CA2489810A1 (fr) 2002-06-25 2003-12-31 Wyeth Utilisation de derives de thio-oxindole dans le traitement de troubles cutanes
US7256218B2 (en) 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
US7507746B2 (en) 2003-02-24 2009-03-24 Mitsubishi Pharma Corporation Enantiomer of tenatoprazole and the use thereof in therapy
AU2004237961A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of bipolar disorders and associated symptoms
CA2525323A1 (fr) 2003-05-16 2004-11-25 Pfizer Products Inc. Procede pour ameliorer les fonctions cognitives en administrant du ziprasidone
WO2004100955A1 (fr) 2003-05-16 2004-11-25 Pfizer Products Inc. Traitements de l'angoisse avec la ziprasidone
BRPI0410378A (pt) 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
ES2377406T3 (es) 2003-07-30 2012-03-27 Xenon Pharmaceuticals Inc. Derivados de la piperazina y su uso como agentes terapéuticos
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (fr) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
WO2005035498A1 (fr) 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. Utilisation d'un compose bicyclique azote comme agent de regulation alimentaire
EP1557166A1 (fr) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Derives d'alpha-aminoamides pour le traitement des désordres de l'appareil urinaire inférieur
US7507760B2 (en) 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
CN1938031A (zh) * 2004-03-29 2007-03-28 默克公司 作为钠通道阻滞剂的联芳取代的吡嗪酮类
BRPI0509307A (pt) 2004-03-29 2007-09-04 Pfizer compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
WO2005099689A1 (fr) 2004-04-01 2005-10-27 Case Western Reserve University Apport topique de phtalocyanines
EP1734951A2 (fr) 2004-04-08 2006-12-27 TopoTarget A/S Composes de diphenyl-indol-2-on et leur utilisation dans le traitement du cancer
CN1953967B (zh) 2004-04-27 2013-03-13 惠氏公司 孕酮受体调节剂的纯化
MXPA06012660A (es) 2004-05-05 2007-03-23 Unibioscreen Sa Derivados de naftalimida para el tratamiento de cancer.
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
MXPA06014573A (es) 2004-06-24 2007-03-12 Incyte Corp Compuestos amido y su uso como farmaceuticos.
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP4677323B2 (ja) 2004-11-01 2011-04-27 キヤノン株式会社 画像処理装置及び画像処理方法
WO2006055752A2 (fr) 2004-11-18 2006-05-26 Incyte Corporation INHIBITEURS DE LA 11-β-HYDROXYSTEROIDE DEHYDROGENASE DE TYPE 1 ET PROCEDES D’UTILISATION
DE102005007694A1 (de) 2005-02-18 2006-09-21 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
JP5248866B2 (ja) 2005-02-22 2013-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｄｍ２の小分子阻害剤およびその使用
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
AU2006242542A1 (en) 2005-04-29 2006-11-09 Wyeth Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
ES2439454T3 (es) * 2005-09-01 2014-01-23 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
JP2009543762A (ja) 2006-06-09 2009-12-10 メルク エンド カムパニー インコーポレーテッド ナトリウムチャネル遮断薬としてのベンゾアゼピノン
WO2008046087A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
CL2007002951A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Uso de compuestos derivados de espiroheterociclicos en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer.
CL2007002953A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
WO2008046082A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés hétérocycliques comme agents thérapeutiques
JP5460324B2 (ja) * 2006-10-12 2014-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド 治療剤としてのスピロ−オキシインドール化合物の使用
WO2008046084A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
WO2008046083A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés oxindole comme agents thérapeutiques
CN101522685A (zh) 2006-10-12 2009-09-02 泽农医药公司 三环螺-吲哚酮衍生物及其作为治疗剂的用途
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2008117050A1 (fr) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazines pyrazolyl-amino substituées et utilisation de ces composés pour le traitement du cancer
WO2008153801A1 (fr) * 2007-05-29 2008-12-18 Intrexon Corporation Ligands diacylhydrazine chiraux destinés à moduler l'expression de gènes exogènes par le biais d'un complexe récepteur de l'ecdysone
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010045197A1 (fr) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
WO2010053998A1 (fr) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Dérivés d'indole spiro-condensés utilisables en tant qu'inhibiteurs des canaux sodiques
US20110269788A1 (en) * 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
WO2010132352A2 (fr) 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Composés spiro et leur utilisation en tant qu'agents thérapeutiques
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011047173A2 (fr) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques à usage oral
CA2788440A1 (fr) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Compositions pharmaceutiques de compose spiro-oxindole pour administration topique et leur utilisation en tant qu'agents therapeutiques.
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Also Published As

Publication number Publication date
PH12015502323A1 (en) 2019-08-19
IL241985A (en) 2017-02-28
HK1203192A1 (en) 2015-10-23
CN104650106A (zh) 2015-05-27
CN102471347B (zh) 2015-07-29
US9480677B2 (en) 2016-11-01
JP2017002085A (ja) 2017-01-05
TWI465452B (zh) 2014-12-21
WO2011002708A1 (fr) 2011-01-06
NZ596903A (en) 2014-04-30
RU2012102896A (ru) 2013-08-10
EP2448943B1 (fr) 2016-03-30
PE20160216A1 (es) 2016-05-11
HRP20160732T1 (hr) 2016-07-15
MX2012000028A (es) 2012-01-30
EP2789617B1 (fr) 2016-08-17
ZA201108960B (en) 2013-03-27
US20170073351A1 (en) 2017-03-16
SG176307A1 (en) 2012-01-30
PT2448943T (pt) 2016-07-12
IL241985A0 (en) 2015-11-30
CL2011003335A1 (es) 2012-05-25
AU2010266549B2 (en) 2015-06-25
EP3156407A1 (fr) 2017-04-19
KR20120101980A (ko) 2012-09-17
US20130072537A1 (en) 2013-03-21
ECSP11011512A (es) 2012-01-31
MX342298B (es) 2016-09-23
PE20120413A1 (es) 2012-05-13
AU2010266549A1 (en) 2012-01-19
JP2015038153A (ja) 2015-02-26
RU2535667C2 (ru) 2014-12-20
IL217285A0 (en) 2012-02-29
ES2578779T3 (es) 2016-08-01
TN2011000664A1 (en) 2013-05-24
SMT201600203B (it) 2016-08-31
IL250314A0 (en) 2017-03-30
HK1168854A1 (zh) 2013-01-11
HRP20110946A2 (hr) 2012-01-31
US8883840B2 (en) 2014-11-11
DK2448943T3 (en) 2016-07-04
EP2448943A1 (fr) 2012-05-09
HUE029658T2 (en) 2017-03-28
MY159099A (en) 2016-12-15
CA2764878C (fr) 2018-08-07
JP2012532107A (ja) 2012-12-13
PH12011502619A1 (en) 2021-06-23
CY1117776T1 (el) 2017-05-17
AR077252A1 (es) 2011-08-10
ES2600160T3 (es) 2017-02-07
SI2448943T1 (sl) 2016-07-29
CN102471347A (zh) 2012-05-23
US20100331386A1 (en) 2010-12-30
CO6470866A2 (es) 2012-06-29
US20150025121A1 (en) 2015-01-22
PL2789617T3 (pl) 2017-02-28
KR101751378B1 (ko) 2017-06-28
EP2789617A1 (fr) 2014-10-15
CA2764878A1 (fr) 2011-01-06
PL2448943T3 (pl) 2016-09-30
US8450358B2 (en) 2013-05-28
BRPI1012129A2 (pt) 2016-03-29
IL217285A (en) 2016-09-29
TW201105677A (en) 2011-02-16

Similar Documents

Publication Publication Date Title
MA33552B1 (fr) Énantiomères de composés de spiro-oxindole et leurs utilisations en tant qu&#39;agents thérapeutiques
MA56508B1 (fr) Inhibiteur de l&#39;egfr pour le traitement du cancer
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA47102B1 (fr) Dérivés de pyrane en tant qu&#39;inhibiteurs de cyp11a1 (cytochrome p450 monooxygénase 11a1)
MA52486B1 (fr) Pyridazinones utilisés en tant qu&#39;inhibiteurs de parp7
MA43169B1 (fr) Composés héterocycliques en tant qu&#39; inhibiteurs pi3k-gamma
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA33745B1 (fr) Piperidines substituees qui accroissent l&#39;activite de p53, et utilisation de ces composes
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d&#39;antagonistes du recepteur p2x7 et procedes d&#39;utilisation
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA51669B1 (fr) Modulateurs de tmem16a
MA35576B1 (fr) Nouveaux composés
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
MA54386B1 (fr) Modulateurs de trex1
EA201000046A1 (ru) Замещенные имидазогетероциклы
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA49127B1 (fr) Dérivés d&#39;indole n-substitués
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA39983A (fr) Dérivés de carboxamide
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MA38410B1 (fr) Composés d&#39;azétidinyloxyphénylpyrrolidine
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique